The FDA released two final guidances on developing drugs for community-acquired bacterial pneumonia and hospital-acquired and ventilator-associated bacterial pneumonia. Both documents include updates to trial populations and statistical considerations for analysis populations.
FDA finalizes guidelines for bacterial pneumonia drugs
Sign up for AIChE SmartBrief
News for chemical engineers
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.